id: pharmacotherapy_access_to_hepatic_decompensation
name: Access to Emerging Pharmacotherapies â†’ Hepatic Decompensation
from_node:
  node_id: pharmacotherapy_access
  node_name: Access to Emerging Pharmacotherapies
to_node:
  node_id: hepatic_decompensation
  node_name: Hepatic Decompensation
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Statins, rifaximin, and SGLT2 inhibitors provide multiple mechanisms including
  anti-inflammatory effects, microbiome modulation, and metabolic improvements'
- 'Step 2: These medications may reduce portal pressure, decrease bacterial translocation,
  and improve hepatic metabolism'
- 'Step 3: Reduction in inflammatory cascades and metabolic dysfunction slows cirrhosis
  progression'
- 'Step 4: Prevention of complications and slower disease progression reduces decompensation
  risk'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Seohyuk Lee and Saad Saffo 2023. "Evolution of care in cirrhosis:
    Preventing hepatic decompensation through pharmacotherapy." *World Journal of
    Gastroenterology*. https://doi.org/10.3748/wjg.v29.i1.61'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:05.367751'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/pharmacotherapy_access_to_hepatic_decompensation.yaml
_category: healthcare_access
